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Evidence from both randomized clinical trials and studies of genetic polymorphisms demonstrates that lowering LDL-cholesterol lowers the risk of cardiovascular events 1 . While statin therapy is effective and safe, an adverse effect that has emerged in meta-analyses of major trials and studies of genetic polymorphisms is a modest increase in glycated hemoglobin (HbA 1c ) levels and the risk of developing diabetes 2, 3 . It remains unclear whether this effect reflects the specific mechanism of action of a statin or whether other approaches to lowering LDL-cholesterol have the same diabetogenic effect 4,5 .
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein of predominantly hepatic origin that reduces the efficacy of hepatic LDL-receptor recycling 6, 7 .
Twelve-week clinical trials of the monoclonal antibody PCSK9 inhibitor, evolocumab, have demonstrated reductions in LDL-cholesterol of around 60% 8, 9 . Two placebo-controlled clinical trials have also confirmed a reduction in cardiovascular events by PCSK9 inhibition.
Results from a single study of 901 participants suggest that evolocumab has no notable effect on measures of glycemia and beta cell function 12 and, in recently published data from the FOURIER trial, there was no effect of evolocumab on new-onset diabetes compared to placebo over 2.2 years 10 . However, genetic findings indicate that PCSK9 variants associated with lower LDL-cholesterol do increase risk of developing diabetes [14] [15] [16] . We therefore examined the effect of evolocumab therapy over 1 year in 2 open-label extension (OLE) studies to determine if this agent has any notable effect on measures of glycemic control, weight, or new-onset diabetes. These 2 OLE studies enrolled participants who had previously completed a qualifying evolocumab parent study.
Methods
Thirteen parent trials [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] fed into the 2 ongoing open-label extension (OLE) randomized controlled trials, OSLER-1 and OSLER-2 29 (see Supplementary Table 1) .
Eleven out of the 13 parent studies were randomized trials that compared evolocumab to placebo or ezetimibe (one was a 52-week trial 21 while the remaining 10 were 12-week trials).
In the other 2 parent studies (6 weeks and 12 weeks), participants only received evolocumab.
At the end of the parent trials, participants had the option to continue into an OLE trial. Those who opted to do so were randomized in a 2:1 ratio to evolocumab plus standard of care (SOC) or to SOC alone for the first year of the OLE trial without regard to treatment allocation in the parent trial. Analyses of the OLE trials were limited to the first year;
following the first year, all randomized participants were offered open-label evolocumab for the remainder of the study. In these OLE trials, background statin therapy could vary as determined by the treating physician. Participants from the parent trials plus the OLE trials provided written informed consent and the trials were approved by all relevant ethics committees and regulatory bodies. Key eligibility criteria for the parent and OLE trials, including specific exclusion criteria related to diabetes, are provided in Supplementary   Table 1 . For the parent trials, the safety population was defined as all randomized participants who received at least 1 dose of study drug. For the OLE trials, the safety population was defined as all randomized participants. Randomization sequences were generated by computer for the trials by the sponsor, Amgen. In OSLER-1, randomization was stratified by treatment arm in the parent study, while in OSLER 2 it was stratified by parent study and frequency of subcutaneous dosing. Each trial was overseen by an independent data monitoring committee.
The main purpose of this analysis was to investigate the effect of 1-year of open-label evolocumab compared to control therapy on glycemia, body weight, and new-onset diabetes mellitus. Evolocumab was administered by subcutaneous injection either in the clinic or by self-administration at the participant's home. All participants entering an OLE study were randomized to receive either evolocumab plus SOC or SOC alone in a 2:1 ratio. 
2). In OSLER-1 weight was measured at baseline and 52 weeks whereas in OSLER-2 weight was measured at baseline and 48 weeks.
To determine if there was any confounding due to parent-study effects, changes in glycemia were examined over the parent-study period in the parent trials of evolocumab. We also compared participants who did or did not enrol in an OSLER trial following completion of a parent study to rule out differences and possible confounding. The methodology applied in the parent trials was very similar to the approach taken in the OLE trials (see
Supplementary information).
T2DM at baseline was defined as medical history of diabetes, baseline HbA 1c ≥6.5%
(48 mmol/mol), baseline fasting plasma glucose ≥7.0 mmol/L, or use of medication for In supportive analyses we compared the effect of evolocumab to control therapy at 12 weeks in the parent studies. Given the possibility that there may have been bias in progression from parent trials to OLE trials based on randomized treatment in the parent trial, we performed a sensitivity analysis to determine whether there were differences between participants who did or did not enrol in an OSLER trial following a parent study.
We also calculated the exposure-adjusted incidence rate per 100 patient years for new onset diabetes, from randomization in the parent trials until the end of year 1 in the OLE trials. Data were analysed using SAS version 9.3. Amgen funded the parent trials and OLE trials, which were designed in collaboration with each trial's investigators. The lead co-authors (N.S., P.P.T. and D.P.) proposed the study and developed the analyses in collaboration with coauthors M.E. and R.S. Amgen was responsible for data collection and analysis.
Results
There were 6,430 participants in the parent trials (4,148 participants randomized to evolocumab and 2,282 to control therapy). Baseline characteristics for participants in the parent trials are provided in Supplementary Figure 1A ) compared with SOC alone.
Pooled data at 12, 24 and 48 weeks is presented for FPG in Figure 1B and for HbA 1c
in Figure 1C . Change in median HbA1c was identical over 48 weeks in both treatment arms, namely 0.1%. Change in median FPG was also very similar between treatment arms over 48
in the analysis of all participants: 0.06mmol/L on evolocumab plus SOC compared to 0.06mmol/L on SOC alone. Subgroup analyses for those with diabetes, without diabetes and at high risk of diabetes were consistent with this lack of effect ( Table 2) . Results at week 12 in a pooled analysis of the 13 parent studies feeding into the OLE trials were consistent with the 1 year OLE results (Supplementary Table 3 ). There was also no difference in change in FPG or HbA1c during the parent trials for those who did (n=4,802) or did not (n=1,628)
subsequently proceed from a parent trial into an OLE trial (Supplementary Table 3 ).
Mean weight change during the OLE trials was 0.3kg on evolocumab plus SOC over 48-52 weeks compared with -0.1kg on SOC alone in an analysis of all participants ( Table 2 ).
In those with diabetes, mean weight change was -0.4kg in participants with evolocumab plus SOC and -0.6kg in participants receiving SOC alone. In participants without diabetes, mean weight change was 0.4kg in participants with evolocumab plus SOC, and was 0.0kg in participants on SOC alone). In participants at high risk for diabetes, mean change in weight was 0.1kg in participants on evolocumab and 0.2kg in participants on SOC alone.
Of those without diabetes at parent-study baseline, the exposure-adjusted incidence of new-onset diabetes per year was 3.85 cases per 100 patient-years on evolocumab/evolocumab plus SOC treatment and 3.69 cases per 100 patient-years on control/SOC alone ( inhibition translates into a reduction in cardiovascular events in high risk patients and that the benefit is comparable to observations from the major statin trials 10, 11 . In addition, these trials have shown no effect of PCSK9 inhibitors on new-onset diabetes, though follow-up was relatively short. The SPIRE trials revealed a small increase in fasting glucose at 1 year but no change in HbA1c. Taken together, data from these trials together with findings in this report are thus reassuring and they effectively rule out any clinically significant medium-term effect of PCSK9 inhibition on measures of glycemia and new-onset diabetes risk. Participants in the evolocumab plus SOC group had a slight increase in weight; however, when we examined subgroups, we found that these changes were driven mostly by participants without diabetes and not at high risk for diabetes. As the OSLER studies were open-label trials where patients and their physicians saw on-label treatment LDL-cholesterol levels, we cannot exclude that a reduction in LDL-C led to more liberal caloric intake by patients receiving evolocumab.
We acknowledge several limitations in our analysis. First, in the OLE trials evolocumab was compared to SOC rather than placebo. Nevertheless, given the potency of LDL-cholesterol reduction with evolocumab along with analysis of objectively measured outcomes, our analyses should be robust. The trials were also relatively short and we therefore acknowledge that we cannot rule out longer-term effects on glycemia. Reassuringly, however, the modest effect of statins on glycemia in patients with diabetes appears most obvious within the first year with little if any deterioration thereafter 30 . Furthermore, length of exposure to evolocumab during the parent-study phase differed between participants, due to both parentstudy treatment assignment and parent-study length. We acknowledge that the number of cases of new-onset diabetes was relatively small in our study compared to the FOURIER trial; however, the current results provide detailed information for glycemia and weight for evolocumab not available elsewhere. Finally, our work represents a post hoc analysis.
In summary, treatment with evolocumab in a 1-year, OLE setting had no apparent effect on glucose homeostasis. SOC: standard of care Data shown as mean ± SD, or count (%) * Parent-study baseline † Defined as previously known T2DM, on glucose-lowering medication, baseline FPG ≥7.0 mmol/L or baseline HbA1c ≥6.5% **History of angina, myocardial infarction, coronary artery bypass graft or percutaneous coronary intervention ‡ Impaired fasting glucose (i.e. fasting plasma glucose 6.1-6.9mmol/L) or HbA1c ≥6.0% at baseline, and not meeting the criteria for T2DM § Median (Q1, Q3) ǁ Available for 1327 participants assigned to SOC alone and 2685 assigned to evolocumab + SOC 6.9 (5.9, 7.9)
[563]
6.5 (6.1, 7.1)
[278]
[542]
89.3 ± 21.1 [198] 88 SOC: standard of care; EvoMab: evolocumab; SD: standard deviation; SE: standard error; wk: week * For columns reporting weight data, data are taken from week 48 in OSLER-2 and week 52 in OSLER-1 † Subset of those with no diabetes, defined as: impaired fasting glucose (i.e. FPG 6.1-6.9 mmol/L) or HbA1c ≥6.0% at baseline, and not meeting the criteria for T2DM
To convert glucose to mg/dL, multiply by 18; to convert LDL-cholesterol to mg/dL, multiply by 38.6 
SUPPLEMENTARY INFORMATION

METHODS
Parent trial analysis
Data were pooled from 13 parent studies (Supplementary Table 1) . Patients, study personnel, investigators, and Amgen study staff were blinded to treatment assignment within dose frequency groups of the parent trials. Blood samples were taken at baseline and week 12.
Data from the 12-week parent trials were pooled and analysed together. Exposure to Evolocumab or control during the parent study was included in the exposure-adjusted new-onset diabetes analysis. Changes in FPG and HbA1c in the parent study were compared between those receiving evolocumab and those receiving control. For change in LDL-cholesterol in the parent trials, the control group was further divided into those allocated placebo and ezetimibe respectively.
SUPPLEMENTARY RESULTS
Parent trial results
Baseline data for parent-study patients is provided in Supplementary 
